Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198143 | 0.82 | KDM4E (0.36) | ALDH1A1CYP1A2TARBP2MAPK1HPGD | |
| SCHEMBL8277834 | 0.81 | RAB9A (0.38) | ALDH1A1CYP1A2MAPK1HPGDKDM4E | |
| SCHEMBL8352410 | 0.81 | NPSR1 (0.45) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL13217488 | 0.80 | KDM4E (0.43) | ALDH1A1CYP1A2TARBP2MAPK1HPGD | |
| SCHEMBL13217093 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP1A2MAPK1HPGDKDM4E | |
| SCHEMBL16268486 | 0.77 | GRK6 (0.42) | ALDH1A1CYP1A2TARBP2MAPK1HPGD | |
| SCHEMBL3369577 | 0.75 | KMT2A (0.44) | ALDH1A1CYP1A2TARBP2KDM4EKMT2A | |
| SCHEMBL16268846 | 0.74 | ESR1 (0.44) | ALDH1A1CYP1A2MAPK1HPGDKMT2A | |
| SCHEMBL5727018 | 0.74 | GAA (0.43) | ALDH1A1CYP1A2TARBP2MAPK1HPGD | |
| SCHEMBL5727260 | 0.74 | KDM4E (0.39) | ALDH1A1CYP1A2TARBP2MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667035-B2 | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-23 | — | — | US | disclosed |
| US-20090023920-A1 | IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INTERMEDIATES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS AND PESTICIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-7439370-B2 | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| WO-2005110999-A1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS INTERMEDIATE PRODUCTS FOR PRODUCING MEDICAMENTS AND PESTICIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023920-A1 | IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INTERMEDIATES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS AND PESTICIDES | CHRM1, CHRM2, CYP3A43 | ALDH1A1 1775/4885CYP1A2 13/4885TARBP2 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.